Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET
Company Participants
Chris Calabrese - LifeSci Advisors, LLC
Alex Sapir - President and Chief Executive Officer
Alan Musso - Chief Financial Officer
Iain Fraser - Interim Chief Medical Officer
Conference Call Participants
Benazir Ali - Stifel
Joe Schwartz - Leerink Partners
Edward Tenthoff - Piper Sandler
Matthew Hagood - Oppenheimer
Operator
Good morning and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investor Section of Fulcrum’s website at www.fulcrumtx.com and is being recorded.
Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines and financial projections. While these forward-looking statements represent Fulcrum's view as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business.
Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer and Dr. Iain Fraser, Interim Chief Medical OfficerAfter providing updates on our key programs, there will be a brief Q&A in which Alex, Alan and Iain will be available to answer your questions.
With that, it is my pleasure to turn the call over to Alex. Sir, you may begin.
Alex Sapir
That's great. Thanks, Tawanda and thanks to all of you for joining us today. We are pleased with the progress that we've made in the third quarter of 2023, advancing our two clinical assets, losmapimod and pociredir. In addition, we remain well capitalized with a cash position of $257 million as of September 30 and have extended our cash runway into 2026 through a strategic review and budget process only on our essential priorities.
So what I'd like to do this morning is provide an update on our two key programs, losmapimod for facioscapulohumeral muscular dystrophy, or FSHD, and pociredir, previously referred to as FTX-6058, for sickle cell disease, after which I'll turn it over to Alan for some financial highlights.